Abstract:Objective: Clinical applications of Glucagon-like peptide-1 receptor agonists (GLP1-RA) were greatly limited due to its short half-life. The current study aims at the formulation and characterization of sustained-release (SR)-GLP1-RAs to prolong the release profile with lag phase-free formulation technology. Methods: The long-acting drugs of those GLP1-RAs were prepared by an ultrasonic spray drying process with biodegradable PLGA polymer. Once the PLGA polymer and each API were dissolved in acetic acid, those were applied to the ultrasonic spray dryer to produce the microspheres which encapsulate the API in PLGA polymer. The pharmacokinetic profiles of long-acting SR-Exenatide, SR-Liraglutide, and SR-Semaglutide were determined by using Sprague-Dawley rats after a single injection subcutaneously. APIs were used as controls. Results: The optimized SR-Exenatide has demonstrated favorable physicochemical properties, such as mean particle size (20 ± 3 μm), percent of entrapment efficiency (90 ± 5 %), and the final drug loading (5 ± 0.5 %), with uniformly sized microspheres. Furthermore, the pharmacokinetic parameters appeared that its release profile extends up to 4 weeks without lag phase which showed 11.4 days of Tmax and 68% of relative bioavailability (BA) when 2mg/kg dose applied. Not only SR-Exenatide but also SR-Liraglutide and SR-Semaglutide showed the extended-release profile up to 1 week and 4 weeks in the rats, respectively. Conclusion: Those results showed the potentials of lag phase-free, long-acting, high productivity, and mass production. Taken together with the lag phase-free formulation and long-acting ultrasonic spray drying technologies, it will provide the rationales for the clinical development of SR-GLP1-RAs for once-weekly or -monthly formulations. As we have a GMP facility to produce long-acting drugs, we will actively and clinically investigate those SR-GLP1-RAs for antidiabetic therapy. Disclosure J. G. Jung: None.

The Modified Exenatide Microspheres: PLGA-PEG-PLGA Gel and Zinc-Exenatide Complex Synergistically Reduce Burst Release and Shorten Platform Stage

Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system

Exenatide-loaded PLGA Microspheres with Improved Glycemic Control: in Vitro Bioactivity and in Vivo Pharmacokinetic Profiles after Subcutaneous Administration to SD Rats.

Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity

Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide

A One-Step Modified Method to Reduce the Burst Initial Release from Plga Microspheres

Double Layer Spherical Nanoparticles with Hyaluronic Acid Coating to Enhance Oral Delivery of Exenatide in T2DM Rats.

Injectable sustained‐release poly(lactic‐co‐glycolic acid) (PLGA) microspheres of exenatide prepared by supercritical fluid extraction of emulsion process based on a design of experiment approach

Microfluidic-Based Preparation of Plga Microspheres Facilitating Peptide Sustained-Release

Improvement of liraglutide release from PLGA microspheres by a porous microsphere-gel composite system

Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies

PLGA sustained-release microspheres loaded with an insoluble small-molecule drug: microfluidic-based preparation, optimization, characterization, and evaluation in vitro and in vivo

A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel.

Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation

Sustained Release Subcutaneous Delivery of BMS-686117, a GLP-1 Receptor Peptide Agonist, Via a Zinc Adduct.

Preparation, Characterization And In Vitro Release Properties Of Ibuprofen-Loaded Microspheres Based On Polylactide, Poly(Epsilon-Caprolactone) And Their Copolymers

Preparation, characterization and in vitro release properties of ibuprofen-loaded microspheres based on polylactide, poly(ε-caprolactone) and their copolymers

Thermal stability of exenatide encapsulated in stratified dissolving microneedles during storage

641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide

Improvement of protein loading and modulation of protein release from poly(lactide-co-glycolide) microspheres by complexation of proteins with polyanions.

Sustained Release of PEG-g-chitosan Complexed DNA from Poly(lactide-Co-glycolide).